Indication: Urothelial Cancer
Retrospective Observational Study to Assess the Efficacy of Anti-PD-(L)1 Treatment in Subjects with Fibroblast Growth Factor Receptor Aberrations
Sub-indication: Urothelial Carcinoma with FGFR Mutation
Line of Therapy: Must have received treatment with at least 1 anti PD- (L)1.
Principal Investigator: Arash Rezazadeh, M.D.Norton Cancer Institute
Sponsor: Janssen Research & Development